Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall...

Dr Neil Gross - MD Anderson Cancer Center, Houston, USA

Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall survival rates in patients with resectable CSCC ( Dr Neil Gross - MD Anderson Cancer Center, Houston, USA )

PARPi combinations to treat patients with mCRPC

Prof Axel Merseburger, Prof Karim Fizazi, Prof Laura-Maria Krabbe and Prof...

PARPi combinations to treat patients with mCRPC ( Prof Axel Merseburger, Prof Karim Fizazi, Prof Laura-Maria Krabbe and Prof Gerhardt Attard )

Where do we stand with mCRPC?

Dr Neal Shore, Prof Neeraj Agarwal, Dr Pasquale Rescigno and Dr Friederike...

Where do we stand with mCRPC? ( Dr Neal Shore, Prof Neeraj Agarwal, Dr Pasquale Rescigno and Dr Friederike Schlurmann )

Selpercatinib benefit, with or without pembro, in first-line advanced RET...

Dr Herbert Ho Fung Loong - The Chinese University of Hong Kong, Hong Kong

Selpercatinib benefit, with or without pembro, in first-line advanced RET fusion-positive NSCLC ( Dr Herbert Ho Fung Loong - The Chinese University of Hong Kong, Hong Kong )

ESMO 2023: Latest updates in mRCC

Dr Javier Puente, Dr Laurence Albiges, Prof Viktor Grünwald and Prof Stéphane...

ESMO 2023: Latest updates in mRCC ( Dr Javier Puente, Dr Laurence Albiges, Prof Viktor Grünwald and Prof Stéphane Oudard )

Induction chemotherapy added to chemoradiation improves PFS and OS in advanced...

Dr Mary McCormack - University College Hospital, London, UK

Induction chemotherapy added to chemoradiation improves PFS and OS in advanced cervical cancer ( Dr Mary McCormack - University College Hospital, London, UK )

Active surveillance for oesophageal cancer shows improved HRQoL compared to...

Dr Berend Van der Wilk - Erasmus MC Cancer Institute, Rotterdam, The Netherlands

Active surveillance for oesophageal cancer shows improved HRQoL compared to standard surgery ( Dr Berend Van der Wilk - Erasmus MC Cancer Institute, Rotterdam, The Netherlands )

Sotorasib and panitumumab demonstrate clinically meaningful benefit in KRAS...

Dr Filippo Pietrantonio - ‎The National Cancer Institute of Milan, Milan, Italy

Sotorasib and panitumumab demonstrate clinically meaningful benefit in KRAS G12C-mutated metastatic colorectal cancer ( Dr Filippo Pietrantonio - ‎The National Cancer Institute of Milan, Milan, Italy )

Datopotamab deruxtecan extends PFS vs chemo for HR+/HER2- breast cancer

Dr Aditya Bardia - Mass General Cancer Center, Boston, USA

Datopotamab deruxtecan extends PFS vs chemo for HR+/HER2- breast cancer ( Dr Aditya Bardia - Mass General Cancer Center, Boston, USA )

Adding nivolumab to neoadjuvant chemo improves response rate for high risk ER+...

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

Adding nivolumab to neoadjuvant chemo improves response rate for high risk ER+ HER2− breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )

Enfortumab vedotin plus pembrolizumab improves overall survival for advanced...

Prof Thomas Powles - Barts Cancer Centre, London, UK

Enfortumab vedotin plus pembrolizumab improves overall survival for advanced bladder cancer ( Prof Thomas Powles - Barts Cancer Centre, London, UK )

Belzutifan improves PFS, ORR in clear cell renal cell carcinoma

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

Belzutifan improves PFS, ORR in clear cell renal cell carcinoma ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

More from ecancer